Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (24285)	8/9/1998 2:25:00 PM
From: Alper H.YUKSEL	Read Replies (5) \| Respond to of 32384

'' the expected milestone payments, or product revenue from Targretin. If both happened (and I think that it is very possible that both will happen) '' Targretin NDA is expected to take place within 1998, right ? Do you think it will be fast-tracked by the FDA ? If that is the case, when would MDs be able to prescribe it ? 2nd half of 1999 ? Do you have any ideas about the sizes of milestone payments in 1999, could you please update about the expected milestones ? When I think that the company has two filed NDAs, one of which is very close to approval, three more NDAs slated for late this year and early 1999, I am quite positive that we'll see SIGNIFICANT appreciation of the stock, late 1998, early 1999. That the size of the targeted populations are small could be construed as a negative sign by some, but I think that the validation of the company's technology platform is more important at this stage and should attract investors. The only thing that could delay the above is a general market crash, which is not unlikely. But still, the biotechs in general are so battered, the downside risk should be limited. On a last note, could you provide some insight regarding approval for additional indications and off-label uses. Based on the discussions in the thread, I understand that once a drug is approved for an indication, it doesn't need to have Phase I for another indication. (But, I also understand that Phase II and III are taking up most of the time and resources anyway). However, MDs can still prescribe the drug for other indications in extreme cases. Is the above correct ? TIA and Regards